Literature DB >> 15063141

Suppression of intestinal polyposis in Apcmin/+ mice by targeting the nitric oxide or poly(ADP-ribose) pathways.

Jon G Mabley1, Pál Pacher, Peter Bai, Rebecca Wallace, Sunali Goonesekera, Laszlo Virag, Garry J Southan, Csaba Szabó.   

Abstract

Min mice have a germ-line nonsense mutation at codon 850 of the adenomatous polyposis coli (Apc) gene. These mice spontaneously develop multiple polyps in the small and large intestine at the age of 10-12 weeks. The aim of this study was to assess the role of reactive nitrogen species and poly(ADP-ribose) synthetase in tumorogenesis. Oxidative stress was found to be increased in the mucosa of the small intestine of Apc(min/+) mice with a concomitant increase in intestinal polyposis over control mice. Pharmacological inhibition of inducible nitric oxide synthase (NOS) with guanidinoethyldisulfide (GED) or stimulation of the breakdown of the nitrogen reactive species peroxynitrite using a potent decomposition catalyst, FP 15, reduced both the intestinal tumor load and the oxidative stress associated with intestinal polyposis in Apc(min/+) mice. Surprisingly, pharmacological inhibition of poly(ADP-ribose) synthetase by the phenanthridinone derivative PJ 34 also reduced the intestinal polyposis and oxidative stress in these mice, possibly through the inhibition of induction of nitric oxide synthase. These results suggest that reactive nitrogen species particularly peroxynitrite play a pivotal role in development of intestinal polyposis and that strategies to reduce both the oxidative stress and the formation of these radical species may be potential chemopreventive approaches for colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063141     DOI: 10.1016/j.mrfmmm.2004.01.006

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

Review 1.  Interplay between DNA repair and inflammation, and the link to cancer.

Authors:  Dawit Kidane; Wook Jin Chae; Jennifer Czochor; Kristin A Eckert; Peter M Glazer; Alfred L M Bothwell; Joann B Sweasy
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-01-13       Impact factor: 8.250

Review 2.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

3.  In vitro and in vivo suppression of cellular activity by guanidinoethyl disulfide released from hydrogel microspheres composed of partially oxidized hyaluronan and gelatin.

Authors:  Lihui Weng; Natalia D Ivanova; Julia Zakhaleva; Weiliam Chen
Journal:  Biomaterials       Date:  2008-08-03       Impact factor: 12.479

Review 4.  Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential.

Authors:  Ines Batinić-Haberle; Júlio S Rebouças; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

5.  Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors.

Authors:  Tünde Kovács; Edit Mikó; András Vida; Éva Sebő; Judit Toth; Tamás Csonka; Anita Boratkó; Gyula Ujlaki; Gréta Lente; Patrik Kovács; Dezső Tóth; Péter Árkosy; Borbála Kiss; Gábor Méhes; James J Goedert; Péter Bai
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

6.  Lithocholic Acid, a Metabolite of the Microbiome, Increases Oxidative Stress in Breast Cancer.

Authors:  Patrik Kovács; Tamás Csonka; Tünde Kovács; Zsanett Sári; Gyula Ujlaki; Adrien Sipos; Zsolt Karányi; Dóra Szeőcs; Csaba Hegedűs; Karen Uray; Laura Jankó; Máté Kiss; Borbála Kiss; Damya Laoui; László Virág; Gábor Méhes; Péter Bai; Edit Mikó
Journal:  Cancers (Basel)       Date:  2019-08-27       Impact factor: 6.639

7.  Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism.

Authors:  Katarína Smolková; Edit Mikó; Tünde Kovács; Alberto Leguina-Ruzzi; Adrienn Sipos; Péter Bai
Journal:  Antioxid Redox Signal       Date:  2020-03-18       Impact factor: 8.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.